Your browser is no longer supported. Please, upgrade your browser.
Settings
RFL Rafael Holdings, Inc. daily Stock Chart
RFL [NYSE]
Rafael Holdings, Inc.
Index- P/E- EPS (ttm)-0.34 Insider Own0.10% Shs Outstand15.75M Perf Week-8.17%
Market Cap247.90M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float12.71M Perf Month-25.61%
Income-4.70M PEG- EPS next Q- Inst Own36.10% Short Float2.65% Perf Quarter-18.53%
Sales4.90M P/S50.59 EPS this Y51.80% Inst Trans-0.02% Short Ratio5.91 Perf Half Y0.51%
Book/sh7.96 P/B1.98 EPS next Y- ROA-3.40% Target Price- Perf Year95.53%
Cash/sh- P/C- EPS next 5Y- ROE-4.10% 52W Range6.90 - 30.86 Perf YTD98.49%
Dividend- P/FCF- EPS past 5Y- ROI-5.30% 52W High-49.00% Beta-
Dividend %- Quick Ratio9.30 Sales past 5Y- Gross Margin- 52W Low128.12% ATR0.93
Employees17 Current Ratio9.30 Sales Q/Q16.70% Oper. Margin- RSI (14)31.73 Volatility5.73% 5.07%
OptionableYes Debt/Eq0.13 EPS Q/Q-254.20% Profit Margin-95.20% Rel Volume0.85 Prev Close15.46
ShortableYes LT Debt/Eq0.13 EarningsOct 14 AMC Payout- Avg Volume57.08K Price15.74
Recom- SMA20-13.43% SMA50-19.18% SMA200-13.71% Volume48,568 Change1.81%
Nov-07-19 02:51PM  Here is What Hedge Funds Think About Rafael Holdings, Inc. (RFL) Insider Monkey
09:00AM  Rafael Pharmaceuticals Joins the Pancreatic Cancer Action Networks Scientific & Medical Affairs Industry Membership GlobeNewswire
Oct-30-19 09:00AM  Rafael Pharmaceuticals Appoints Chief Medical Officer, José Octávio Costa Filho, M.D. GlobeNewswire
Oct-29-19 01:37PM  What Kind Of Shareholder Appears On The Rafael Holdings, Inc.'s (NYSEMKT:RFL) Shareholder Register? Simply Wall St.
Oct-28-19 09:00AM  Rafael Pharmaceuticals Reaches Milestone of 25 Active Sites for Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) GlobeNewswire
Oct-24-19 09:00AM  Rafael Pharmaceuticals Announces Expansion into South Korea of Pivotal Phase 3 Trial of CPI-613® (devimistat) in Patients with Metastatic Pancreatic Cancer GlobeNewswire
Oct-17-19 09:00AM  Rafael Pharmaceuticals Enters into Collaboration with the National Institutes of Health (NIH) to Test CPI-613® (devimistat) in Cytokine Independent (Acute) HTLV-1 Associated Adult T-cell Leukemia/Lymphoma GlobeNewswire
Oct-08-19 09:00AM  Rafael Pharmaceuticals Reaches Milestone of 100 Patients Enrolled in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613® (devimistat) for Patients with Metastatic Pancreatic Cancer GlobeNewswire
09:00AM  Rafael Pharmaceuticals Congratulates Scientific Advisory Board Member Gregg L. Semenza For Receiving 2019 Nobel Prize in Medicine GlobeNewswire
Oct-03-19 07:39PM  Rafael Holdings Reports Fourth Quarter and Full Fiscal Year 2019 Results PR Newswire
Oct-02-19 09:00AM  Rafael Pharmaceuticals Appoints Wendy McDermott to Chief People Officer GlobeNewswire
Sep-19-19 09:00AM  Rafael Pharmaceuticals Announces Expansion into South Korea of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) GlobeNewswire
Sep-17-19 09:00AM  Rafael Pharmaceuticals Announces Expansion into France of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613® (devimistat) in Combination with Modified FOLFIRINOX as First-Line Treatment for Patients with Metastatic Pancreatic Cancer GlobeNewswire -6.70%
Sep-16-19 09:00AM  Peer-Reviewed Journal Future Oncology Publishes Two Manuscripts on Cancer Metabolism and Drug Candidate CPI-613® (Devimistat) GlobeNewswire
Aug-27-19 03:43PM  We Think Rafael Holdings (NYSEMKT:RFL) Has A Fair Chunk Of Debt Simply Wall St.
Aug-05-19 09:35AM  LipoMedix Appoints New Members to Board of Directors and Creates New Executive Committee GlobeNewswire
09:00AM  Rafael Pharmaceuticals Launches Clinical Trial Web Portal Rafael Trial Connect GlobeNewswire
Aug-01-19 10:15AM  Rafael Pharmaceuticals Announces Expansion into Austria, South Korea and Spain of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) GlobeNewswire
Jul-30-19 04:15PM  David A. Polinsky, Esq Appointed to the Board of Directors of Innovative Food Holdings, Inc. GlobeNewswire
Jul-18-19 10:40AM  Rafael Pharmaceuticals Announces Expansion into Israel of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613® (devimistat) in Combination with Modified FOLFIRINOX as First-Line Treatment for Patients with Metastatic Pancreatic Cancer GlobeNewswire
Jun-25-19 12:25PM  Introducing Rafael Holdings (NYSEMKT:RFL), The Stock That Zoomed 155% In The Last Year Simply Wall St. +10.58%
08:00AM  Rafael Pharmaceuticals Enters into Out-Licensing Agreement with Ono Pharmaceutical to Accelerate Clinical Development and Commercialization of Cancer Drug Candidate CPI-613® (devimistat) in Japan and Other Asian Countries GlobeNewswire
Jun-06-19 08:00AM  Sanjeev Luther, President and CEO of Rafael Pharmaceuticals, Named Finalist for The 2019 EY Entrepreneur Of The Year® Award in New Jersey GlobeNewswire
Jun-05-19 09:02AM  Rafael Holdings Reports Third Quarter Fiscal Year 2019 Results PR Newswire
Jun-04-19 08:00AM  Rafael Pharmaceuticals to Present at the 2019 Jefferies Global Healthcare Conference GlobeNewswire
May-16-19 01:05PM  Sanjeev Luther, President and CEO of Rafael Pharmaceuticals, to be Honored by American Cancer Society at Annual Starry Night Gala GlobeNewswire
07:17AM  Do Directors Own Rafael Holdings, Inc. (NYSEMKT:RFL) Shares? Simply Wall St.
May-13-19 08:00AM  Rafael Pharmaceuticals Appoints Senior Vice President for Clinical Development and Operations GlobeNewswire -5.48%
Mar-29-19 03:00PM  LipoMedix to Present New Clinical Data on Promitil® at American Association for Cancer Research (AACR) Annual Meeting 2019 GlobeNewswire
Mar-12-19 04:30PM  Rafael Holdings Reports Second Quarter Fiscal Year 2019 Results PR Newswire +7.34%
Mar-08-19 07:30AM  Rafael Holdings to Report Second Quarter Fiscal Year 2019 Results PR Newswire
Mar-04-19 11:15AM  Lipomedix Announces Initiation of Phase 1b Trial (LIPORAD-2018) of Promitil® in Combination with Radiotherapy in Patients with Advanced Cancer. GlobeNewswire
Feb-07-19 08:55AM  Devimistat (CPI-613®) to be Explored in a New Combination for T-Cell Lymphoma Treatment as Part of Stand Up To Cancers T-Cell Lymphoma Dream Team Research Grant GlobeNewswire
Jan-23-19 05:30PM  Rafael Holdings Acquires Majority Stake in Rafael Pharma PR Newswire -8.27%
Jan-17-19 08:00AM  Rafael Pharmaceuticals to Present Plan for Phase 3 Trial (AVENGER 500) of devimistat (CPI-613®) in Combination with Modified FOLFIRINOX as a First Line Treatment for Metastatic Pancreatic Cancer at 2019 Gastrointestinal Cancers Symposium GlobeNewswire +12.95%
Jan-15-19 08:26AM  Old West Investment Management 4th Quarter 2018 Commentary GuruFocus.com +6.19%
Jan-10-19 11:00AM  EMA Grants Orphan Drug Designation to Rafael Pharmaceuticals devimistat (CPI-613®) for Treatment of Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) GlobeNewswire +30.00%
08:00AM  EMA Grants Orphan Drug Designation to Rafael Pharmaceuticals devimistat (CPI-613®) for Treatment of Metastatic Pancreatic Cancer GlobeNewswire
Jan-09-19 01:15PM  UPDATED RELEASE: Rafael Pharmaceuticals Announces Initiation of Patient Enrollment for Phase II Clinical Trial of CPI-613 for Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia GlobeNewswire
08:00AM  Rafael Pharmaceuticals Announces Initiation of Phase II Trial of CPI-613 in Combination with Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer GlobeNewswire
Jan-08-19 08:00AM  Rafael Pharmaceuticals Announces Initiation of Patient Enrollment for Phase II Clinical Trial of CPI-613 for Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia GlobeNewswire
Jan-07-19 08:00AM  Rafael Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-11-18 08:00AM  Rafael Pharmaceuticals Announces Initiation of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 (devimistat) in Combination with Modified FOLFIRINOX as First Line Treatment for Patients with Metastatic Pancreatic Cancer GlobeNewswire +5.76%
Dec-10-18 04:49PM  Rafael Holdings Reports First Quarter Fiscal Year 2019 Results PR Newswire
Dec-06-18 03:38PM  Rafael Holdings to Report First Quarter Fiscal Year 2019 Results PR Newswire
Dec-05-18 10:00PM  Rafael Holdings to Present at LD Micro Investor Conference PR Newswire
Nov-29-18 09:10AM  Rafael Pharmaceuticals Announces Initiation of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613 (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) GlobeNewswire
Nov-06-18 08:55AM  Rafael Pharmaceuticals Appoints Vice President, Manufacturing and CMC Regulatory Affairs and Vice President of Regulatory Affairs to Strengthen Development of CPI-613 GlobeNewswire
Oct-15-18 09:05AM  Rafael Holdings Reports Fourth Quarter and Full Fiscal Year 2018 Results PR Newswire
08:55AM  Rafael Pharmaceuticals to Present at BIO Investor Forum 2018 GlobeNewswire
Oct-09-18 08:55AM  Rafael Pharmaceuticals to Present at BIO Investor Forum 2018 GlobeNewswire
Oct-05-18 08:30AM  Rafael Holdings to Report Fourth Quarter and Full Fiscal Year 2018 Results PR Newswire
Sep-21-18 12:45PM  Rafael Holdings to Present at Sidoti Fall 2018 Investor Conference PR Newswire
Sep-07-18 08:30AM  Rafael Holdings Increases Stake in Rafael Pharma PR Newswire
Aug-16-18 10:55AM  Rafael Pharmaceuticals Receives FDA Orphan Drug Designation of CPI-613 for the Treatment of Peripheral T-Cell Lymphoma (PTCL) GlobeNewswire
Aug-13-18 11:15AM  Rafael Pharmaceuticals Announces Activation of Second Clinical Trial Site for the Phase I Study of CPI-613 in Patients with Relapsed or Refractory T-Cell Lymphoma GlobeNewswire
Jul-09-18 10:39AM  5 Spinoff Stocks That Outperform Their Parents InvestorPlace
Jul-06-18 08:30AM  Rafael Holdings to Ring the NYSE Opening Bell PR Newswire
Jun-11-18 08:30AM  Rafael Holdings Reports Third Quarter Fiscal Year 2018 Results PR Newswire
Jun-07-18 03:12PM  Rafael Holdings to Report Third Quarter Fiscal Year 2018 Results PR Newswire
May-17-18 09:47AM  Should You Be Concerned About Rafael Holdings Incs (NYSEMKT:RFL) Investors? Simply Wall St.
Mar-27-18 08:30AM  IDT Completes Spin-Off of Rafael Holdings PR Newswire
Rafael Holdings, Inc. owns commercial real estate assets and interests in clinical pharmaceutical companies. The company operates in two segments, Real Estate and Pharmaceuticals. It engages in the lease of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.